New oral drug kamlanoflast enters human testing for ALS
NCT ID NCT07396818
First seen Feb 11, 2026 · Last updated Jun 15, 2026 · Updated 30 times
Summary
This study tests an oral drug called Kamlanoflast in 40 adults with ALS. The goal is to see if it is safe, tolerable, and can reduce inflammation or slow disease progression over 24 weeks. Participants must be 18-75 years old, diagnosed with ALS within the last 3 years, and have signs of worsening function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.